Grace Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Grace Therapeutics, Inc. (GRCE) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
Operating Activities
Net Income-9.57-12.85-42.43-9.82-19.68-25.51-39.37
Depreciation & Amortization0.010.010.120.000.922.322.33
Deferred Income Tax-3.20-1.83-9.54-0.650.000.000.00
Stock Based Compensation0.730.911.811.341.170.000.00
Change in Working Capital0.34-1.280.18-2.79-5.95-3.226.19
Change in Accounts Receivable0.600.08-0.30-0.020.060.000.00
Change in Accounts Payable0.00-1.650.41-2.39-6.700.000.00
Change in Other Working Capital-0.250.290.07-0.380.700.000.00
Other Operating Activities-3.223.6435.75-6.223.243.070.16
Net Cash from Operating Activities-14.90-12.33-15.91-17.23-14.32-22.95-24.79
Investing Activities
Capital Expenditures0.000.090.020.00-0.070.32-0.53
Purchases of Investments-0.02-6.5513.17-3.52-9.790.000.00
Sales/Maturities of Investments0.020.0213.1731.41-9.798.46-8.91
Net Cash from Investing Activities0.000.1013.15-3.52-9.868.14-9.44
Financing Activities
Debt Repayment0.000.000.000.000.00-1.560.00
Common Stock Issued15.007.340.300.0059.636.9844.89
Other Financing Activities-0.97-0.160.000.00-0.140.010.00
Net Cash from Financing Activities14.037.360.300.0059.4913.1845.69
Summary
Effect of Forex Changes on Cash0.000.00-0.010.151.39-1.00-1.01
Net Change in Cash-0.87-4.87-2.46-20.6036.70-2.6311.46
Cash at Beginning of Period23.0127.8530.3450.9414.24-14.676.42
Cash at End of Period22.1322.9827.8830.3450.94-17.3016.87
Free Cash Flow-14.90-12.36-15.93-17.23-14.39-23.27-25.32